FIELD: biochemistry.
SUBSTANCE: presented is chimeric, CDR-imparted, humanized or recombinant human antibody or its fragment which specifically binds to human EFNA4. Also disclosed is conjugate of above antibody with cytotoxic agent. Disclosed is pharmaceutical composition and method of treating EFNA4-associated disorder.
EFFECT: invention extends range of controlling EFNA4-associated disorders.
51 cl, 20 dwg, 5 tbl, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW MODULATORS AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2627176C2 |
| HUMANISED ANTI-CXCR4 ANTIBODIES FOR TREATING CANCER | 2011 |
|
RU2595394C2 |
| ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | 2012 |
|
RU2658603C2 |
| ANTIBODIES TO HER3 AND APPLICATION THEREOF | 2010 |
|
RU2560583C2 |
| ANTI-CXCR4 ANTIBODIES AND USING THEM FOR TREATING CANCER | 2009 |
|
RU2573897C2 |
| ALLOSTERIC ANTIBODIES AGAINST HUMAN HER3 NON COMPETITIVE FOR NEUREGULIN AND USE THEREOF | 2013 |
|
RU2704228C2 |
| SPECIFIC LINKING AGENTS AGAINST B7-H1 | 2010 |
|
RU2571204C2 |
| EPHRINE B2 ANTIBODIES AND METHODS FOR USING THEM | 2007 |
|
RU2451031C2 |
| CSF-1R ANTIBODY | 2009 |
|
RU2547586C2 |
| NOVEL ANTIBODY FOR DIAGNOSIS AND/OR PROGNOSIS OF CANCER | 2011 |
|
RU2651513C2 |
